论文部分内容阅读
本文介绍了CA19－9免疫放射分析方法的临床应用，其中测定96名正常人血清的平均值为8．32±7．23U／mL，73名结-直肠患者血清（包括DukeA、B、C、D期）的平均值分别为9．68±5．32U／mL、12．87±10．14U／mL、71．11±90．53U／mL、297．55±255．11U／mL。60例胰腺癌血清平均值为196．12±208．30U／mL。若以30U／mL为阳性界值，其结一直肠癌DukeA、B、C、和D期阳性率分别为0％、13．8％、46．7％和87．5％。胰腺癌阳性率为80％。正常人假阳性率为1．04％。本文还应用ROC分析法论证CA19－9IRMA在临床中的应用价值。
This article describes the clinical application of CA19-9 immunoradiometric assays, in which the average of 96 normal human sera was determined to be 8.32±7.23 U/mL, and 73 patients with colorectal cancer (including Duke A, B, C, The average value of D phase) was 9.68±5.32 U/mL, 12.87±10.14 U/mL, 71.11±90.53 U/mL, and 297.55±255.11 U/mL, respectively. The average serum level of 60 cases of pancreatic cancer was 196.12±208.30 U/mL. With 30 U/mL as a positive cutoff, the positive rates of Duke A, B, C, and D in colon cancer were 0%, 13.8%, 46.7%, and 87.5%, respectively. The positive rate of pancreatic cancer was 80%. The normal false positive rate was 1.04%. This article also applied ROC analysis to demonstrate the clinical value of CA19-9IRMA.